Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated nearly $36.7 billion in FY 2025 revenue and about $7.7 billion in net income, while Iovance Biotherapeutics posted $263.5 million in revenue but a $391.0 million net loss. The article favors Amgen as the steadier 2026 choice, citing its 21.0% net margin, $8.1 billion in free cash flow, and dividend support, versus Iovance’s higher-risk, unprofitable growth profile. Key risks remain Amgen’s biosimilar, pricing, and litigation exposure, and Iovance’s manufacturing, reimbursement, and clinical adoption uncertainty.

Analysis

AMGN is the cleaner expression of “cash now, optionality later.” In a tape where the market is rewarding durable free cash flow and capital return over story risk, its biggest advantage is not just profitability but the ability to absorb pricing pressure, fund pipeline breadth, and still defend shareholder payouts. The hidden benefit is that a large, diversified pharma can actually gain relative share if smaller biotechs run into reimbursement, manufacturing, or safety friction — physicians and payers tend to consolidate around incumbent therapies when adoption costs rise.

IOVA remains a classic binary-capital structure: the science can work, but commercialization is constrained by throughput, center onboarding, and payer economics, so growth can decelerate sharply even if clinical data stay intact. The market is likely underestimating how sensitive this name is to operational execution rather than just clinical readouts; a single quarter of weaker treatment starts can re-rate the stock faster than any long-dated pipeline optimism can repair it. That makes the runway useful, but not investable by itself — dilution risk becomes the real hidden variable once commercial momentum stalls.

The second-order setup favors AMGN over a 6-18 month horizon, especially if patent cliffs and biosimilar noise widen the valuation gap without materially changing cash generation. The main contrarian point is that AMGN’s leverage and wholesaler concentration create a false sense of defensiveness; in a policy shock, its earnings power can compress faster than investors expect. Still, on a risk-adjusted basis the market is paying for certainty in AMGN and paying for hope in IOVA, which is usually the right trade only when the hope side has a visible inflection path — that is not yet fully established here.

Key Decisions for Investors

• Long AMGN vs short IOVA as a 6-12 month pair trade; thesis is cash-flow resilience versus execution/dilution risk. Target 15-25% relative outperformance to AMGN, stop if IOVA demonstrates two consecutive quarters of accelerating treatment volume and gross margin leverage.
• Sell cash-secured puts on AMGN 3-6 months out on 5-8% pullbacks; use the trade to express willingness to own a cash generator at a cheaper entry while collecting premium from low-volatility compression.
• Avoid outright long IOVA ahead of major commercial milestones unless sized as a small option-like position; the correct structure is calls or call spreads, not stock, because downside from a miss is likely larger and faster than upside from a beat.
• If IOVA weakens on another revenue/launch miss, consider a tactical short into any post-print bounce for 2-8 weeks; the market is likely to punish lack of operating leverage before it rewards long-dated pipeline optionality.
• Watch AMGN for policy or channel-discount headlines; if pricing rhetoric intensifies, hedge with healthcare ETF protection rather than exiting the core long, since the business quality remains superior to single-name risk.